ReviewNucleic acid therapeutics2012
Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression.
Review in Nucleic acid therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 66 citations in OpenAlex.
- Transfer RNA-derived small RNAs in female reproductive disorders: emerging roles and clinical implications.Journal of assisted reproduction and genetics · 2026Review
- The NTE domain of PTENα/β promotes cancer progression by interacting with WDR5 via its SSSRRSS motif.Cell death & disease · 2024Article
- miR-1246 promotes osteosarcoma cell migration via NamiRNA-enhancer network dependent on Argonaute 2.MedComm · 2024Article
- The Emerging Function and Promise of tRNA-Derived Small RNAs in Cancer.Journal of Cancer · 2024Review
- PSMC3 promotes RNAi by maintaining AGO2 stability through USP14.Cellular & molecular biology letters · 2022Article
- RNA binding proteins in MLL-rearranged leukemia.Experimental hematology & oncology · 2022Review
- tRF3008A suppresses the progression and metastasis of colorectal cancer by destabilizing FOXK1 in an AGO-dependent manner.Journal of experimental & clinical cancer research : CR · 2022Article
- Expression of tiRNA and tRF inAnnals of translational medicine · 2021Article
- MicroRNA 195-5p TargetsInternational journal of molecular sciences · 2021Article
- Double-Stranded RNA Binding Proteins in Serum Contribute to Systemic RNAi Across Phyla-Towards Finding the Missing Link in Achelata.International journal of molecular sciences · 2020Article
- Action mechanisms and research methods of tRNA-derived small RNAs.Signal transduction and targeted therapy · 2020Review
- Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Review
- The Emerging Role of Major Regulatory RNAs in Cancer Control.Frontiers in oncology · 2019Review
- Transfer RNA-derived fragments and tRNA halves: biogenesis, biological functions and their roles in diseases.Journal of molecular medicine (Berlin, Germany) · 2018Review
- Non-coding RNAs and retroviruses.Retrovirology · 2018Review
- Epigenetic regulation of alternative splicing.American journal of cancer research · 2018Review
- Intron-specific shRNA-mediated downregulation of survivin and promotion of apoptosis in HeLa cells.Oncology letters · 2017Article
- Stable association of RNAi machinery is conserved between the cytoplasm and nucleus of human cells.RNA (New York, N.Y.) · 2016Article
- Wilms Tumor Suppressor, WT1, Cooperates with MicroRNA-26a and MicroRNA-101 to Suppress Translation of the Polycomb Protein, EZH2, in Mesenchymal Stem Cells.The Journal of biological chemistry · 2016Article
- Transcriptional silencing of long noncoding RNA GNG12-AS1 uncouples its transcriptional and product-related functions.Nature communications · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Small RNAs are a commonly used tool for gene silencing and a promising platform for nucleic acid drug development. They are almost exclusively used to silence gene expression post-transcriptionally through degradation of mRNA. Small RNAs, however, can have a broader range of function by binding to Argonaute proteins and associating with complementary RNA targets in the nucleus, including long noncoding RNAs (lncRNAs) and pre-mRNA. Argonaute-RNA complexes can regulate nuclear events like transcription, genome maintenance, and splicing. Thousands of lncRNAs and alternatively spliced pre-mRNA isoforms exist in humans, and these RNAs may serve as natural targets for regulation and therapeutic intervention. This review describes nuclear mechanisms for Argonaute proteins and small RNAs, new pathways for sequence-specific targeting, and the potential for therapeutic development of small RNAs with nuclear targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.